keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma with portal vein thrombosis

keyword
https://www.readbyqxmd.com/read/28240515/portal-vein-thrombosis-in-unresectable-hcc-cases-a-single-center-study-of-prognostic-factors-and-management-in-140-patients
#1
Ahmed Hosni Abdelmaksoud, Safaa Mandooh, Mohamed Mahmoud Nabeel, Tamer Mahmoud Elbaz, Hend Ibrahim Shousha, Ashraf Monier, Inas Anwar Elattar, Ashraf Omar Abdelaziz
Objective: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). The aim of our study was to evaluate the prognostic factors and management in patients with hepatocellular carcinoma with portal vein thrombosis (PVT). Methods: Between February 2011 and February 2015, 140 patients presented to our specialized multidisciplinary HCC clinic. All were assessed by imaging at regular intervals for tumor response and the data compared with baseline laboratory and imaging characteristics obtained before treatment...
January 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28228906/histological-assessment-of-the-efficacy-of-drug-eluting-beads-in-portal-tumor-thrombosis-of-hepatocellular-carcinoma
#2
Yusuke Imai, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Hiroaki Tanaka, Mie Kurata, Sohei Kitazawa, Yoichi Hiasa
A 58-year-old man was diagnosed with advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The tumors were multiple and existed in both lobes. Drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) was performed for the tumors in the left lobe. Embosphere and Hepasphere were selected for embolization of the arterioportal shunt, followed by loaded epirubicin infusion into the left hepatic artery. Computed tomography showed reduction of PVTT. However, liver failure progressed, and the patient died 67 days after DEB-TACE...
March 2017: Radiology case reports
https://www.readbyqxmd.com/read/28223736/percutaneous-electrochemotherapy-in-the-treatment-of-portal-vein-tumor-thrombosis-at-hepatic-hilum-in-patients-with-hepatocellular-carcinoma-in-cirrhosis-a-feasibility-study
#3
Luciano Tarantino, Giuseppina Busto, Aurelio Nasto, Raffaele Fristachi, Luigi Cacace, Maria Talamo, Catello Accardo, Sara Bortone, Paolo Gallo, Paolo Tarantino, Riccardo Aurelio Nasto, Matteo Nicola Dario Di Minno, Pasquale Ambrosino
AIM: To treated with electrochemotherapy (ECT) a prospective case series of patients with liver cirrhosis and Vp3-Vp4- portal vein tumor thrombus (PVTT) from hepatocellular carcinoma (HCC), in order to evaluate the feasibility, safety and efficacy of this new non thermal ablative technique in those patients. METHODS: Six patients (5 males and 1 female), aged 61-85 years (mean age, 70 years), four in Child-Pugh A and two in Child-Pugh B class, entered our study series...
February 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28208001/predictive-factors-for-complete-response-and-recurrence-after-transarterial-chemoembolization-in-hepatocellular-carcinoma
#4
Shin Ok Jeong, Eui Bae Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Sang Gyune Kim, Sang Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Dong Erk Goo, Su Yeon Park
Background/Aims: To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). Methods: Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS). Results: Eighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43...
February 17, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28194035/recurrently-deregulated-lncrnas-in-hepatocellular-carcinoma
#5
Yang Yang, Lei Chen, Jin Gu, Hanshuo Zhang, Jiapei Yuan, Qiuyu Lian, Guishuai Lv, Siqi Wang, Yang Wu, Yu-Cheng T Yang, Dongfang Wang, Yang Liu, Jing Tang, Guijuan Luo, Yang Li, Long Hu, Xinbao Sun, Dong Wang, Mingzhou Guo, Qiaoran Xi, Jianzhong Xi, Hongyang Wang, Michael Q Zhang, Zhi John Lu
Hepatocellular carcinoma (HCC) cells often invade the portal venous system and subsequently develop into portal vein tumour thrombosis (PVTT). Long noncoding RNAs (lncRNAs) have been associated with HCC, but a comprehensive analysis of their specific association with HCC metastasis has not been conducted. Here, by analysing 60 clinical samples' RNA-seq data from 20 HCC patients, we have identified and characterized 8,603 candidate lncRNAs. The expression patterns of 917 recurrently deregulated lncRNAs are correlated with clinical data in a TCGA cohort and published liver cancer data...
February 13, 2017: Nature Communications
https://www.readbyqxmd.com/read/28181172/discrepant-imaging-findings-of-portal-vein-thrombosis-with-dynamic-computed-tomography-and-computed-tomography-during-arterial-portography-in-hepatocellular-carcinoma-possible-cause-leading-to-inappropriate-treatment-selection
#6
Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Kazuyuki Mizuno, Natsuko Kobayashi, Yosuke Inukai, Akira Takeda, Yasuhiro Sone
We encountered a patient with hepatocellular carcinoma who had discrepant imaging findings on portal vein thrombosis with portal phase dynamic computed tomography (CT) and CT during arterial portography (CTAP). CTAP, via the superior mesenteric artery and via the splenic artery, both showed a portal perfusion defect in the right hepatic lobe, indicating portal vein thrombosis in the main trunk of the right portal vein. Portal phase dynamic CT clearly depicted portal perfusion of the same hepatic area. Transarterial chemoembolization was successfully performed, but it was associated with severe liver injury...
April 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28170405/treatment-algorithm-based-on-the-multivariate-survival-analyses-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-trans-arterial-chemoembolization
#7
Hasmukh J Prajapati, Hyun S Kim
PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). METHODS: Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE...
2017: PloS One
https://www.readbyqxmd.com/read/28150309/portal-systemic-shunt-between-the-hepatic-portal-vein-and-right-renal-vein-in-a-patient-with-multifocal-hepatocellular-carcinoma-case-report
#8
Mateja Sabol Pušić, Ivan Budimir, Zdravko Dorosulić, Branko Ostrički, Marko Nikolić, Gordana Lovrenčić Prpić, Katherina B Sreter
Portal hypertension is a clinical syndrome characterized by the development of collateral circulation and portosystemic shunts, as well as ascites and hepatic encephalopathy. We present the case of a large portosystemic shunt between the hepatic portal vein and aneurysmal right renal vein in a cirrhotic 64-year-old man with thrombosis of the portal vein and hepatocellular carcinoma. This is a very rare clinical manifestation which, to our knowledge, has been described only once previously in the literature...
February 2, 2017: Journal of Clinical Ultrasound: JCU
https://www.readbyqxmd.com/read/28133933/the-possibility-of-radiotherapy-as-downstaging-to-living-donor-liver-transplantation-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#9
LETTER
Jin Y Choi, Jeong I Yu, Hee C Park, C H David Kwon, Jong M Kim, Jae-Won Joh, Gyu-Seong Choi, Jae B Park, Sung J Kim, Seung H Lee, Won-Tae Cho, Kyo W Lee, Byeong-Gon Na, Dong Kyu Oh, Nuri Lee, Chan W Cho, Sanghoon Lee, Suk-Koo Lee
No abstract text is available yet for this article.
April 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28110540/portal-vein-thrombosis-in-patients-with-cirrhosis-undergoing-elective-transjugular-intrahepatic-portosystemic-shunt
#10
Wan Yue-Meng, Yu-Hua Li, Hua-Mei Wu, Jing Yang, Li-Hong Yang, Ying Xu
Portal vein thrombosis (PVT) is a common complication in cirrhosis. The aim of this study was to determine risk factors for PVT, assess the efficacy of anticoagulant therapy, and evaluate the effects of PVT on patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt (TIPSS). A total of 101 patients with cirrhosis undergoing elective TIPSS were prospectively studied. After TIPSS, all patients received preventive therapy for PVT and were followed up at 3, 6, 12, and 24 months...
January 1, 2017: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28109767/thromboelastometry-hypercoagulable-profiles-and-portal-vein-thrombosis-in-cirrhotic-patients-with-hepatocellular-carcinoma
#11
Alberto Zanetto, Marco Senzolo, Alessandro Vitale, Umberto Cillo, Claudia Radu, Francesca Sartorello, Luca Spiezia, Elena Campello, Kryssia Rodriguez-Castro, Alberto Ferrarese, Fabio Farinati, Patrizia Burra, Paolo Simioni
BACKGROUND: Cirrhotic patients with hepatocellular carcinoma (HCC) exhibit hypercoagulability. AIM: We investigated whether thromboelastometry can detect hypercoagulability in these patients and the association with portal vein thrombosis (PVT). METHODS: At baseline, cirrhotic patients with and without HCC underwent thromboelastometry. PVT onset was recorded over a 12-month follow-up period. RESULTS: Seventy-six patients (41 with and 35 without HCC) were included...
December 26, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28104144/pancreas-transplantation-after-liver-transplantation-a-case-report
#12
J H Ryu, T B Lee, Y M Park, K H Yang, C W Chu, J H Lee, B H Choi
Our aim was to describe the clinical indications, surgical technique, and clinical outcomes of a pancreas transplantation, performed 4 years after liver transplantation, as treatment for new-onset, uncontrolled diabetes mellitus in a 53-year-old man. Liver transplantation was performed for end-stage liver disease secondary to hepatitis B virus infection and hepatocellular carcinoma. The patient had no history of diabetes prior to the liver transplantation. The decision to proceed with a pancreas transplantation was made when the patient's blood sugar levels could not be normalized despite insulin doses >100 IU/d...
January 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28078806/prognostic-factors-of-hepatocellular-carcinoma-patients-with-portal-vein-tumor-thrombosis-treated-with-transcatheter-arterial-chemoembolization
#13
Hongyuan Liang, Peng Cui, Qiyong Guo, Xiaonan Mao, Feng Wen, Wei Sun, Ming Shan, Zaiming Lu
AIM: To investigate the factors that influence survival of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) following transarterial chemoembolization (TACE). METHODS: Retrospectively enrolled HCC patients with PVTT (n = 57). Patients received TACE, and the local tumor response was evaluated by modified response evaluation criteria in solid tumor (mRECIST). Overall survival and disease progression were evaluated using Kaplan-Meier survival curves...
January 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28053537/comparison-of-intra-arterial-chemoembolization-with-and-without-radiotherapy-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-a-meta-analysis
#14
Qianqian Zhao, Kunli Zhu, Jinbo Yue, Zhonghua Qi, Shumei Jiang, Xiaoqing Xu, Rui Feng, Renben Wang
PURPOSE: Numerous studies have tried to combine transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) with radiotherapy (RT) for the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). However, the efficacy of TACE or HAIC combined with RT versus TACE or HAIC alone remains controversial. Thus, we performed a meta-analysis to compare the efficacy and safety of intra-arterial chemoembolization combined with RT versus intra-arterial chemoembolization alone for the treatment of HCC patients with PVTT...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28050234/how-to-assess-the-efficacy-or-failure-of-targeted-therapy-deciding-when-to-stop-sorafenib-in-hepatocellular-carcinoma
#15
REVIEW
Jean-Luc Raoul, Xavier Adhoute, Marine Gilabert, Julien Edeline
Sorafenib is thus far the only systemic treatment for hepatocellular carcinoma (HCC) based on the results of two randomized controlled trials performed in Western and in Eastern countries, despite a poor response rate (from 2% to 3.3%) following conventional evaluation criteria. It is now recognized that the criteria (European Association of the Study of the Liver criteria, modified response evaluation criteria in solid tumors) based on contrast enhanced techniques (computed tomography scan, magnetic resonance imaging) aimed to assess the evolution of the viable part of the tumor (hypervascularized on arterial phase) are of major interest to determine the efficacy of sorafenib and of most antiangiogenic drugs in patients with HCC...
December 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27999803/efficacy-of-external-beam-radiation-based-treatment-plus-locoregional-therapy-for-hepatocellular-carcinoma-associated-with-portal-vein-tumor-thrombosis
#16
Ming-Yang Chen, Yu-Chao Wang, Tsung-Han Wu, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Ngan-Ming Tsang, Kun-Ming Chan, Wei-Chen Lee
Background. Portal vein tumor thrombosis (PVTT) is a common event in advanced hepatocellular carcinoma (HCC). The optimal treatment for these patients remains controversial. Methods. A retrospective review of 149 patients who had unresectable HCC associated with PVTT between January 2005 and December 2012 was performed. Outcomes related to external beam radiation-based treatment were measured, and clinicopathological features and parameters affecting prognosis were analyzed as well. Results. The radiotherapeutic response of PVTT was an important element that affected the overall treatment response of HCC...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27920652/diffuse-infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-completely-cured-by-transcatheter-arterial-chemoembolization-case-report-with-8-year-follow-up
#17
Suk Bae Kim
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and its treatment options are determined by shape, liver function, loci, and stages of cancer. Diffuse type of infiltrative HCC accompanied by portal vein tumor thrombosis (PVTT) has the poorest prognosis among other HCCs and there are no other prominent treatment options than systemic chemotherapy. In this study, we report a case of a 56-year-old man with diffuse infiltrative HCC accompanied by PVTT who achieved complete remission for 8 years after receiving conventional transcatheter arterial chemoembolization using adriamycin and gelfoam...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27904861/a-recent-advance-in-image-guided-locoregional-therapy-for-hepatocellular-carcinoma
#18
REVIEW
Yaoping Shi, Bo Zhai
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related deaths. Hepatic resection and liver transplantation are considered to be the preferred treatment for HCC. However, as novel therapeutic options such as image-guided locoregional therapies have emerged and been refined, the manner in which HCC is treated has changed dramatically compared with what it was considered just 2 decades earlier. SUMMARY: This study reviews the current results of various image-guided locoregional therapies for treating HCC, especially focusing on thermal ablative and transarterial techniques...
October 2016: Gastrointestinal Tumors
https://www.readbyqxmd.com/read/27904450/survival-of-patients-with-intermediate-stage-hepatocellular-carcinoma-treated-with-superselective-transarterial-chemoembolization-using-doxorubicin-loaded-dc-bead-under-cone-beam-computed-tomography-control
#19
Peter Popovic, Borut Stabuc, Rado Jansa, Manca Garbajs
BACKGROUND: The purpose of this retrospective study was to evaluate treatment response, adverse events and survival rates of patients with intermediate stage HCC treated with superselective doxorubicin-loaded DC Bead transarterial chemoembolization (DEBDOX) under cone beam computed tomography (CBCT) control. PATIENTS AND METHODS: Between October 2010 and June 2012, 35 consecutive patients with intermediate stage HCC (32 male, 3 female; average age, 67.5 ± 7.8 years; 22 patients Child-Pugh class A, 8 class B, 5 without cirrhosis) were treated with DEBDOX TACE...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27895433/complete-response-with-sorafenib-and-transcatheter-arterial-chemoembolization-in-unresectable-hepatocellular-carcinoma
#20
Michitoshi Takano, Takashi Kokudo, Yoshihiro Miyazaki, Yumiko Kageyama, Amane Takahashi, Katsumi Amikura, Hirohiko Sakamoto
Patients with advanced hepatocellular carcinoma (HCC) showing portal vein tumor thrombosis (PVTT) have an extremely poor prognosis. According to treatment guidelines, the only option for HCC patients with PVTT is sorafenib chemotherapy. However, in Asia, various treatments have been attempted and possible prolongation of overall survival has been repeatedly reported. We herein report the first case of a patient with an initially unresectable advanced HCC with PVTT who underwent curative hepatectomy after sorafenib and transcatheter arterial chemoembolization (TACE) showing complete histological response...
November 14, 2016: World Journal of Gastroenterology: WJG
keyword
keyword
77310
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"